2-(2-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol | 4546-54-7

• 物质功能分类: 生物化工 - 核苷类药物 - 核苷中间体
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-(2-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 4546-54-7
• 化学式: C₁₀H₁₃N₅O₄
• 分子量: 267.24
• InChiKey: JVOJULURLCZUDE-UHFFFAOYSA-N

物化性质

• 熔点：
  105-115°C
• 沸点：
  711.8±70.0 °C(Predicted)
• 密度：
  2.08±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO（轻微）、甲醇（轻微、加热）、水（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

安全信息

• 海关编码：
  2933599090

制备方法与用途

(2R,3R,4S,5R)-2-(2-氨基-9H-嘌呤-9-基)-5-(羟甲基)四氢呋喃-3,4-二醇（9-呋喃戊基-9H-嘌呤-2-胺）是一种嘌呤核苷类似物。这类化合物具有广泛的抗肿瘤活性，特别是针对惰性淋巴系统恶性肿瘤。其抗癌机制主要依赖于抑制DNA合成和诱导细胞凋亡等过程。

文献信息

• MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20210238595A1

  公开（公告）日：2021-08-05

  One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The antisense strand of the dsRNA molecule comprises at least one thermally destabilizing nucleotide occurring at a seed region; the dsRNA comprises at least four 2′-fluoro modifications, and the sense strand of the dsRNA molecule comprises ligand, wherein the ligand is an ASGPR ligand. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
• Modified RNA Agents with Reduced Off-Target Effect
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20220290145A1

  公开（公告）日：2022-09-15

  One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The antisense strand of the dsRNA molecule comprises at least one thermally destabilizing nucleotide occurring at a seed region; the dsRNA comprises at least four 2′-fluoro modifications, and the sense strand of the dsRNA molecule comprises ligand, wherein the ligand is an ASGPR ligand. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.